Free tool
FAERS Monitor: Mozobil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022311 or its brand name (Mozobil, Plerixafor). Reports on generic versions are filed under their own applications.
Reports
1,485
Serious
1,174
79% of reports
Hospitalization
479
Death reported
244
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- febrile neutropenia144
- off label use127
- diarrhoea100
- pyrexia86
- mucosal inflammation83
- nausea82
- thrombocytopenia82
- death60
- plasma cell myeloma60
- pneumonia58
- neutropenia57
- vomiting57
- dyspnoea55
- drug ineffective54
- acute kidney injury46
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 20 |
| 2010 | 41 |
| 2011 | 73 |
| 2012 | 114 |
| 2013 | 74 |
| 2014 | 49 |
| 2015 | 53 |
| 2016 | 48 |
| 2017 | 69 |
| 2018 | 62 |
| 2019 | 107 |
| 2020 | 139 |
| 2021 | 204 |
| 2022 | 86 |
| 2023 | 75 |
| 2024 | 127 |
| 2025 | 94 |
| 2026 | 50 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,674 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mucosal inflammationSignal | 83 | 45.0 | 36.5 | 3,524 |
| febrile neutropeniaSignal | 144 | 30.8 | 26.4 | 4,128 |
| plasma cell myelomaSignal | 60 | 21.8 | 17.0 | 1,171 |
| thrombocytopeniaSignal | 82 | 10.4 | 8.4 | 690 |
| neutropeniaSignal | 57 | 5.9 | 4.6 | 231 |
| acute kidney injurySignal | 46 | 4.3 | 3.2 | 112 |
| pyrexiaSignal | 86 | 3.5 | 2.9 | 155 |
| pneumoniaSignal | 58 | 2.5 | 2.0 | 53 |
| diarrhoeaSignal | 100 | 2.2 | 1.8 | 66 |
| off label useSignal | 127 | 2.1 | 1.7 | 71 |
| vomiting | 57 | 1.7 | 1.3 | 17 |
| nausea | 82 | 1.5 | 1.2 | 12 |
| dyspnoea | 55 | 1.4 | 1.1 | 5 |
| death | 60 | 1.0 | 0.8 | 0 |
| drug ineffective | 54 | 0.6 | 0.4 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.